Gondola Medical Technologies SA

Gondola Medical Technologies is a Swiss company active in the field of medical devices to address walking and balance symptoms due to neurological disorders. The first target population is Parkinson's Disease (PD) patients, focusing on gait impairments, balance, and mobility challenges that are key motor symptoms of the disease. Current pharmaceutical and surgical treatments, such as dopaminergic medications and Deep Brain Stimulation (DBS), only partially address these symptoms and do not slow disease progression. Gait issues, such as freezing of gait (FoG) and balance problems, often worsen over time, leading to reduced mobility and independence in PD patients.

Gondola Medical Technologies has developed AMPS therapy (Automated Mechanical Peripheral Stimulation), an innovative, non-invasive technology designed to address mobility deficits in PD patients. It involves application of mechanical stimulation to specific areas of both feet to activate neurological pathways that positively impact gait, balance, and FoG. AMPS therapy can be used alongside existing PD treatments, with complementary effectiveness to dopaminergic medications and DBS.

AMPS technology has been tested on thousands of PD patients with positive results, showing significant improvement in gait, balance, and FoG. AMPS technology provides a personalized, easy-to-use home therapy, developed to address the current unmet need for improving gait and mobility deficits in PD patients, and acting complementary to dopaminergic and DBS therapies.

Gondola Medical Technologies is positioned as a crucial medical technology innovation addressing mobility challenges in Parkinson's patients, with the potential to significantly improve patient outcomes and quality of life.

The company's mission is to make Gondola® a global standard of care for the treatment for gait and mobility deficits in PD patients and its vision is to improve the quality of life of patients with neurological disorders suffering from gait and mobility deficits.